Roles
- Professor of Ophthalmology
- Member of the Graduate Program for the Department of Biochemistry and Molecular Biology
- Secondary Appointment of Biochemistry and Molecular Biology
-
Biography
Byron L. Lam, M.D. is a clinician and a researcher with a focus in neuro-ophthalmology, hereditary retinal disease, and ophthalmic epidemiology. He is a professor of ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School in Medicine and is the holder of the Robert Z. & Nancy J. Greene Chair in Ophthalmology.
Dr. Lam is an active clinical scientist. His clinical practice focuses on patients with neuro-ophthalmology conditions or inherited retinal disease. This broad background in neuro-ophthalmology and hereditary retinal degenerations has enabled him to collaborate with basic and clinical scientists resulting in many successful translational projects. Throughout his career, he has performed numerous neuro-ophthalmology studies including Leber hereditary optic neuropathy gene therapy, idiopathic intracranial hypertension cerebrospinal fluid dynamics, and anterior ischemic optic neuropathy,
His profound interest in inherited retinal disease and electrophysiology led him to carry out numerous gene therapy and novel therapeutic clinical trials in conditions such as retinitis pigmentosa, achromatopsia, and Stargardt disease. Of interest, Dr. Lam conducted the first US choroideremia gene therapy clinical trial as IND holder, sponsor, and principal investigator. To better quantitate visual light sensitivity as a clinical trial endpoint, Dr. Lam created and validated the Visual Lightsensitivity Questionnaire – 8 (VLSQ-8) and along with the biomedical team developed the Bascom Palmer Light Discomfort Analyzer to quantitatively determine ocular light discomfort.
His ability to effectively integrate clinical and basic science and to make important connections between them is demonstrated by the textbook he authored in 2005: Electrophysiology of Vision; Clinical Testing and Applications. The book is among the most popular text in its field and is used by students, physicians-in-training, researchers and clinicians. Dr. Lam has also been involved in ocular epidemiologic research on how visual impairment increases mortality through indirect pathways such as its effect on the activities of daily living and well-being.
In addition to his clinical practice and research activities, Dr. Lam is medical director of clinical research and medical director of neuro-ophthalmology service at Bascom Palmer as well as scientific co-director of the Adrienne Arsht Hope for Vision Retinal Degeneration Laboratory. He Lam is on the editorial board of American Journal of Ophthalmology and received the Senior Achievement Award from the American Academy of Ophthalmology. -
Teaching Interests
My main teaching focus is to teach residents and fellows to enable them to have clinical expertise in neuro--ophthalmology and inherited retinal disease. I am particular interested in teaching the next generation of educators, clinicians and researchers in these areas. I have participated in medical student lectures and CME conferences extensively throughout my career. I have also served on PhD dissertation committees. -
Research Interests
I am a clinical scientist with research focus in neuro-ophthalmology, hereditary retinal disease, and ophthalmic epidemiology.
I have performed and participated in numerous clinical translational neuro-ophthalmology studies throughout my career with the focus in providing better patient care. I have performed numerous neuro-ophthalmology studies involving a broad spectrum of conditions including Leber hereditary optic neuropathy gene therapy, idiopathic intracranial hypertension cerebrospinal fluid dynamics, and anterior ischemic optic neuropathy,
I have been involved in clinical translational research in hereditary retinal diseases and have carried out numerous gene therapy and novel therapeutic clinical trials in conditions such as retinitis pigmentosa, achromatopsia, and Stargardt disease.
I also have an interest in visual function testing and novel retinal imaging techniques. For example, to better quantitate visual light sensitivity as a clinical trial endpoint, I created and validated the Visual Lightsensitivity Questionnaire – 8 (VLSQ-8) and along with the biomedical team developed the Bascom Palmer Light Discomfort Analyzer to quantitatively determine ocular light discomfort.
I have a longstanding research interest in ophthalmic epidemiology with the goals of furthering population-based strategies for improving vision health and collaborating with experts in advanced statistical modeling techniques to demonstrate the broad effects that visual impairment has on functional status and mortality. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Shaping the Future of Eye Care
The Mark J. Daily Inherited Retinal Diseases Research Center Celebrated with Ribbon Cutting
Bascom Palmer Establishes New Center Dedicated to Inherited Retinal Diseases
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 42 clinical trials.
-
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
- Principal Investigator: Byron Lam
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Closed
-
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration
- Principal Investigator: Byron Lam
- Study Phase: N/A
- Enrollment Status: Closed
-
Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26")
- Principal Investigator: Byron Lam
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec in US
- Principal Investigator: Byron Lam
- Study Phase: Other
- Enrollment Status: Not Accepting
-
XLRP is currently defined as an incurable genetic disease that causes blindness. The disease is caused by a defect in a certain gene located on the X-chromosome, and this is why the disease affects men and women differently.The long-term objective is to find out if vision in patients suffering from XLRP can be preserved by replacing the defective RPGR gene using this gene therapy. However, this is the first time that AAV8-RPGR will have been administered in humans, and therefore, a correct dose of AAV8-RPGR still needs to be determined with a single sub-retinal injection. The purpose of this study is to assess safety of RPGR at different dose levels.
- Principal Investigator: Byron Lam
- Study Phase: Phase II/III
- Enrollment Status: Open
-
The study will enroll approximately 200 subjects with XLRP with RPGR mutation. The sample size is limited by subject availability due to the orphan’ nature of the disease. Given this is a non-interventional study, no hypothesis testing will be performed and formal sample size calculation is not applicable.Both eyes will be analysed for all subjects. Continuous variables (including changes from Visit 1) will be summarised over time using descriptive statistics (i.e., mean, standard deviation, 95% confidence interval [CI], median, Q1, Q3, P05, P95, min and max). Categorical variables (including shifts from Visit 1) will be described over time using counts, percentages and 95% CIs.Changes from Visit 1 in BCVA will be tabulated over time. The remaining continuous functional and anatomical outcomes will be displayed over time with their change from Visit 1. For categorical functional and anatomical outcomes, the number of subjects with an assessment will be presented at each visit with the percentage of subjects in each category. Shifts from Visit 1 will also be summarised by visit.Statistical tests will be exploratory, 2-sided, and performed at the alpha level of 0.05 (unless otherwise specified).
- Principal Investigator: Byron Lam
- Study Phase: Other
- Enrollment Status: Open
-
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects With Choroideremia Previously Treated With Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects With X-Linked Retinitis Pigmentosa Previously Treated With Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study
- Principal Investigator: Byron Lam
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
The goals of this study are to find out whether Tinlarebant can slow the rate of STGD1 disease progression, and in turn slow the loss of visual function. To see how safe Tinlarebant is for subjects with STGD1 by monitoring for any side effects. To see what Tinlarebant does to the body (known as pharmacodynamics”).
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Not Accepting
-
OpCT-001 is an investigational cell therapy product composed of photoreceptor precursor (PRP) cells derived from human induced pluripotent stem cells (iPSCs).The primary objective of the study is to evaluate the safety and tolerability of sub retinal injection of OpCT-001 in participants with primary photoreceptor disease.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia With Bilateral, Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)
- Principal Investigator: Byron Lam
- Study Phase: Phase 2
- Enrollment Status: Open
-
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with STGD1 confirmed genotypically to have bi-allelic autosomal recessive ABCA4 gene mutations.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
To assess the efficacy, safety, and tolerability of administering a single, sequential, unilateral/bilateral subretinal dose of OCU400 in study participants with Retinitis Pigmentosa
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
This study is an open-label, single ascending dose (SAD) clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human (FIH) clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single sub retinal (sub macular) injection of ACDN-01.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
- Principal Investigator: Byron Lam
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Not Accepting
-
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
- Principal Investigator: Byron Lam
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Not Accepting
-
A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)
- Principal Investigator: Byron Lam
- Study Phase: Phase 3
- Enrollment Status: Closed
-
The BPEI Ocular Photosensitivity Analyzer emits a light stimulus through a concave array panel composed of 210 LEDs placed at 50cm. The array produces up to 32,000 lux. The computer-controlled instrument is programmed for a 2 sec exposure at 4 sec inter-stimulus interval. The test can be performed under either manual or autonomous modes. In the manual mode, the investigator changes the light stimuli. In the autonomous mode, the computer presents different light stimuli. This technique utilizes random ascending and descending steps, and the subject is instructed to press a button to indicate when the light intensity is uncomfortable. The test is completed after 10 response reversals, and the threshold is calculated from the mean of these responses. It posses a reliability Indices using catch trials. The data can be registered and recorded by the computer. A camera with a 6.5 pixels/mm resolution and the LabVIEW software were included to record, in high-resolution infrared video, the subject responses. A voice demand was added to the devise to avoid human error, when instructing the participant about this test. The study subject can select from two different options (English and Spanish) the idiom they would feel more comfortable with.
- Principal Investigator: Byron Lam
- Study Phase: N/A
- Enrollment Status: Closed
-
The objectives of this study is to clinically characterize a population of individuals with achromatopsia caused by CNGA3 mutations in order to study their progression and stability of clinical parameters and identify any inclusion/exclusion criteria for future clinical trials.Individuals with a confirmed diagnosis of achromatopsia and previously documented disease-causing mutations in both alleles of the CNGA3gene will be asked to provide informed consent to participate in the study.their clinical condition. Some of the testing will include routine ophthalmic examination and tests of visual acuity, color vision, perimetry, nystagmus, photoaversion (light discomfort), optical coherence tomography, electroretinography, fundus photography and completion of a quality of life questionnaire. Patients who are enrolled in the US, a single blood or saliva sample will be drawn for DNA sequence analysis of the five gene known to cause achromatopsia (unless previously tested), and adaptive optics retinal imaging will be performed on each patient at least one occasion.
- Principal Investigator: Byron Lam
- Study Phase: N/A
- Enrollment Status: Closed
-
Evaluate the natural history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) using swept source optical coherence tomography angiography (SS-OCTA).
- Principal Investigator: Byron Lam
- Study Phase: N/A
- Enrollment Status: Closed
-
An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA
- Principal Investigator: Byron Lam
- Study Phase: Phase 1
- Enrollment Status: Not Accepting
-
Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS)
- Principal Investigator: Byron Lam
- Study Phase: Other
- Enrollment Status: Not Accepting
-
The objectives of this study are to utilize MRIderived CSF, arterial, and venous flow measures to further the understanding of pathophysiology of disorders with increased intracranial hypertension including idiopathic intracranial hypertension (IIH). The study will include comparison of MRI derived measures to those of matched controls as well as to investigate the MRIderived measures longitudinal in IIH patients including the effects of LP and treatment. This is an interdisciplinary collaborative project between neuroophthalmology and radiology and aims to assess noninvasively by MRI venographic, morphologic, and biomechanics quantitative characteristics of the craniospinal system in intracranial hypertension. Ophthalmic clinic data and measures such as visual acuity, visual fields, and fundus photos will be obtained. In addition, MR venography will be used to assess primary and secondary pathways of cerebral venous drainage. Velocity encoding based imaging of the CSF flow through the aqueduct will be used to assess Supratentorial CSF production rates. Conventional 3D T1weighted MRI scans will be used to quantify the volumes of the ventricular spaces. We hypothesize that changes in CSF production rates will be associated with change in CSF volumes and therefore in ventricular volumes. Data collected during this pilot study will enable us to assess the potential role of 1) the functionality of the venous drainage, b) the CSF production rates, and c) the relative contribution of the spinal canal compartment to the craniospinal compliance.
- Principal Investigator: Byron Lam
- Study Phase: N/A
- Enrollment Status: Closed
-
Study SB-110-007 will investigate the efficacy, safety, and tolerability of repeat doses of sepofarsen in subjects with LCA10 due to the c.2991+1655A>G mutation.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
The purpose of this research study is to assess the performance of the Ocular Photosensitivity Analyzer (OPA) device. In particular, we are interested in examining the repeatability of different ways of estimating your sensitivity to light with this device.
- Principal Investigator: Byron Lam
- Study Phase: Other
- Enrollment Status: Not Accepting
-
You have been invited to participate in this portion of the research study because you have been told that you have X-linked retinitis pigmentosa (XLRP) and have been previously treated in the RPGR-001 XLRP gene therapy study or in a separate XLRP study. XLRP is a genetic (inherited) eye disease that affects cells in the retina (the lining of the back of the eye that detects light) and causes night blindness and gradual worsening of your vision. The purpose of this Phase 2 Study is to see if the investigational study drug, AGTC-501, works to preserve and/or improve your vision and other symptoms of XLRP in the eye that was not previously treated (referred to as the “fellow eye”) in a previous XLRP study. Safety and tolerability of the study drug will also be tested in this study. If you meet the requirements and decide to join this study, you will receive the study drug in your fellow eye. You will be assigned to one of three groups. The first two groups will receive either a high dose or a lower dose, along with a standard (regular) corticosteroid regimen. The third group will receive the high dose, along with a modified (different) corticosteroid regimen to assess how well your eye heals at a lower corticosteroid dose, if this lower dose reduces potential side effects related to the corticosteroids described in the “Main Risks Related to Treatment with Concomitant Medications” section, and if this lower dose of corticosteroids is able to reduce the chance of having eye inflammation (swelling) which may occur after you are given the study drug. The group you are assigned will have a specific dose level and is based on when you enter the trial. You, your study team, the sponsor, and those working with the sponsor, will know which study drug dose and corticosteroid regimen you will receive. In total, we plan to enroll about 18 male participants in this study.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Closed
-
The purpose of the study is to evaluate the safety and tolerability of ATSN-201 delivered subretinally in male subjects 12 years of age with RS1-associated XLRS. Also, To determine the change from Baseline in visual acuity, function, macular structure and subject-reported visual function after a single subretinal injection of ATSN-201.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
Evaluation of the safety and tolerability of a single injection of SPVN06 in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene, 12 months after administration of gene therapy.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
The primary purpose of this study is to assess the safety of unilateral sub retinal administration of OCU410ST in subjects with Stargardt Disease.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
Registry Objectives1. Genotype Characterization2. Cross-Sectional Phenotype Characterization (within gene)3. Establish a Link to My Retina Tracker Registry (MRTR)4. Ancillary Exploratory Studies – Pooling of GenesNatural History Study Objectives1. Natural History (within gene)2. Structure-Function Relationship (within gene)3. Risk Factors for Progression (within gene)4. Ancillary Exploratory Studies – Pooling of Genes
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
The objective of the single ascending dose (SAD)study is to evaluate the safety and tolerability ofsingle doses of intravitreally administered VP-001 inparticipants with confirmed PRPF31 mutation associatedretinal dystrophy.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Not Accepting
-
To assess the long-term safety and tolerability of a single intravitreal injection of Multi-Characteristic Opsin (MCO-010)
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
The purpose of this study is to evaluate the efficacy and safety of the Oral N-Acetylcysteine in patients with Retinitis Pigmentosa
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
AGTC-501, also designated as rAAV2tYF-GRK1-RPGR, is a nonreplicating,rep/cap-deleted, rAAV vector that carries a human codon optimized RPGR-ORF15 gene. The vector contains AAV serotype 2 inverted terminal repeats and an expression cassette composed of a human G protein-coupled receptor kinase 1 (GRK1) promoter, a human RPGR-ORF15 cDNA optimized for efficient codon usage and improved sequence stability during production, a splice donor/splice acceptor sequence, and an SV40 polyadenylation sequence. It is packaged in anAAV2 capsid containing tyrosine to phenylalanine (YF) mutations in three surface-exposed tyrosine residues (AAV2tYF). It is produced using a replication-defective herpes simplex virus helper system in baby hamster kidney cells and purified by column chromatography.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
The purpose of this research study is to assess the ability of the MLYMT to test functional vision in patients with very low vision.Approximately 35 people aged 18 years and older will participate in this study. Participants will include up to 25 individuals with very low vision and 10 individuals with normal vision.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Closed
-
This study has as a primary objective to assess the safety and tolerability of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010); 1.2E11 gc/eye, in subjects with Stargardt Disease. It is expected that a total of up to 6 study subjects will be enrolled. Enrolled subjects will undergo safety and efficacy assessments for 48 weeks from the injection in the study eye. After completion, subjects will be eligible to roll over into a separate long-term observational study.
- Principal Investigator: Byron Lam
- Study Phase: Phase II
- Enrollment Status: Open
-
This is an open-label, multi-center, multiple dose, dose escalation, safety, tolerability and efficacy study of EA-2353 in subjects with retinitis pigmentosa. Four unilateral intravitreal injections into the study eye with each injection performed 1 week apart. The primary objective of the study is to evaluate the safety and tolerability of escalating doses of EA-2353 administered via intravitreal injection in subjects with retinitis pigmentosa (RP). This study will enroll up to 15 evaluable subjects comprising 4 cohorts.
- Principal Investigator: Byron Lam
- Study Phase: Phase I/II
- Enrollment Status: Not Accepting
-
The primary objective of this study is to determine the safety of two doses and two dosing regimens of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Not Accepting
-
This is a natural history study, for subjects with Autosomal Dominant Optic Atrophy with an objective to evaluate the rate of change in structural and functional neuro-ophthalmic parameters in patients =8 to =60 years of age. Secondary objectives of this study are to: Identify optimal assessments of clinical progression of optic atrophy Identify instruments for measuring neuro-ophthalmic parameters Assess Quality of Life in ADOA patients Conduct exploratory analyses of factors associated with disease progression
- Principal Investigator: Byron Lam
- Study Phase: Other
- Enrollment Status: Not Accepting
-
This is a multicenter, open-label, dose ranging study divided in two phases, I and II, and in three subgroups of subjects with three consecutive cohorts. A total of 18 subjects with at least 6 subjects from each of the following subgroups will be selected:1. Biallelic autosomal recessive NR2E3 mutations2. Autosomal dominant NR2E3 mutation3. Autosomal dominant RHO mutationsThe primary endpoint is to assess the safety of unilateral subretinal administration of OCU400 in subjects with retinitis pigmentosa associated with NR2E3 and RHO mutations. The secondary endpoint is to assess humoral and cellular immune responses to OCU400 and shedding of the viral vector.
- Principal Investigator: Byron Lam
- Study Phase: Phase I/II
- Enrollment Status: Not Accepting
-
This phase 3, randomized, multicenter, vehicle-controlled, double-masked study is designed to evaluate the efficacy and safety of intranasal cenegermin (180 g) compared with vehicle control in adult participants with NAION.Participants who sign informed consent will undergo screening (visit 1) to determine study eligibility for enrollment.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
To evaluate the safety and tolerability of laruparetigene zovaparvovec administered bilaterally via subretinal injection in participants with XLRP with a confirmed pathogenic variant in the RPGR gene.To evaluate changes in visual function after bilateral subretinal injection of laruparetigene zovaparvovec.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Open
-
The goal of treatment is to slow or halt disease progression by normalizing genetic transcription to preserve retinal cells and to halt debilitating visual disability and eventual blindness in this population.
- Principal Investigator: Byron Lam
- Study Phase: TBD
- Enrollment Status: Not Accepting
